Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Jan 1;30(1):1-2.
doi: 10.1200/JCO.2011.38.2747. Epub 2011 Nov 21.

Reporting of adjuvant breast cancer trials: when is the right time?

Helena M Earl
Editorial

Reporting of adjuvant breast cancer trials: when is the right time?

Helena M Earl. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30:11–18. - PubMed
    1. Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC) J Clin Oncol. 2010;28(suppl 15; abstr 531):75s.
    1. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol. 2009;10:1145–1151. - PubMed
    1. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–1862. - PubMed
    1. Earl HM, Vallier A, Hiller L, et al. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR) J Clin Oncol. 2009;27(suppl 15; abstr 522):12s.

MeSH terms